InMed Pharmaceuticals Inc. Quarterly Debt-to-equity in % from Q1 2021 to Q4 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
InMed Pharmaceuticals Inc. quarterly Debt-to-equity history and growth rate from Q1 2021 to Q4 2023.
  • InMed Pharmaceuticals Inc. Debt-to-equity for the quarter ending December 31, 2023 was 29.6 %, a 7.42% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2023 29.6 -2.37 -7.42% Dec 31, 2023
Q3 2023 28.3 -9.55 -25.2% Sep 30, 2023
Q2 2023 21.1 -10.6 -33.3% Jun 30, 2023
Q1 2023 26.1 -3.97 -13.2% Mar 31, 2023
Q4 2022 31.9 +7.23 +29.3% Dec 31, 2022
Q3 2022 37.9 +11.8 +45.1% Sep 30, 2022
Q2 2022 31.7 -3.82 -10.8% Jun 30, 2022
Q1 2022 30.1 -5.6 -15.7% Mar 31, 2022
Q4 2021 24.7 Dec 31, 2021
Q3 2021 26.1 Sep 30, 2021
Q2 2021 35.5 Jun 30, 2021
Q1 2021 35.7 Mar 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.